ANNX Annexon

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at . A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is harnessing neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – neurodegenerative, ophthalmic and autoimmune diseases – and includes investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver potentially game-changing therapies to patients so that they can live their best lives. When they thrive, we thrive. To learn more visit .

Investor Contact:

Joyce Allaire

LifeSci Advisors, LLC

 

Media Contact:

Sheryl Seapy

Real Chemistry

949-903-4750



EN
13/11/2024

Underlying

ANNXAnnexon

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Annexon

 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listin...

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 10, 2024, in accordance wit...

December 16, 2024 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Announces Positive Topline Results from Real-World Evidence St...

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across ...

December 16, 2024 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Pho...

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity Pivotal Phase 3 ARCHER II in GA with Data Expected Second Half 2026 BRISBANE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living w...

December 5, 2024 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, an...

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atrophy (GA); Topline Data Expected Second Half 2026 Proof-of-Concept Study with First-in-Kind Oral C1s Inhibitor ANX1502 Transitioned to an Enhanced Tablet Formulation; Data in Cold Agglutinin Disease (CAD) Exp...

November 14, 2024 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Biosciences to Present at the Jefferies London Healthcare Conf...

Annexon Biosciences to Present at the Jefferies London Healthcare Conference BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT. A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at . A replay of the ...

November 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch